Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/107990/1/bjh12906.pd
The use of non-pegylated liposomal doxorubicin (Myocet®) in diffuse large B-cell lymphoma (DLBCL) ha...
Background: The introduction of rituximab (R) to conventional CHOP chemotherapy for newly diagnosed ...
This study was made possible by funding from TEVA Pharmaceuticals.JMS has received honoraria from Ro...
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/110862/1/cncr29113.pd
More recently, DLBCL has witnessed advances in the molecular profiling and treatment of patients wit...
Prokop Vodicka, Pavel Klener, Marek Trneny First Department of Medicine, First Faculty of Medicine, ...
DLBCL is an aggressive lymphoma treated with R-CHOP. Recently, attempts have been made to improve th...
Background: Diffuse large B cell lymphoma (DLBCL) is one of the most common types of non-Hodgkin's l...
In very-elderly diffuse large B-cell lymphoma (DLBCL) patients, treatment intensities must be lowere...
The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II ...
The use of non-pegylated liposomal doxorubicin (Myocet®) in diffuse large B-cell lymphoma (DLBCL) ha...
open12noAn update at 7 years was conceived for our multicenter phase II study in which 55 elderly hi...
Rituximab has improved response rates and overall survival in B-cell lymphoma (DLBCL). Radiotherapy ...
Diffuse large B-cell lymphoma (DLBCL) is the most frequently-occurring type of malignant lymphoma in...
Rajni Sinha1, Loretta J Nastoupil2, Christopher R Flowers11Department of Hematology/Medical Oncology...
The use of non-pegylated liposomal doxorubicin (Myocet®) in diffuse large B-cell lymphoma (DLBCL) ha...
Background: The introduction of rituximab (R) to conventional CHOP chemotherapy for newly diagnosed ...
This study was made possible by funding from TEVA Pharmaceuticals.JMS has received honoraria from Ro...
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/110862/1/cncr29113.pd
More recently, DLBCL has witnessed advances in the molecular profiling and treatment of patients wit...
Prokop Vodicka, Pavel Klener, Marek Trneny First Department of Medicine, First Faculty of Medicine, ...
DLBCL is an aggressive lymphoma treated with R-CHOP. Recently, attempts have been made to improve th...
Background: Diffuse large B cell lymphoma (DLBCL) is one of the most common types of non-Hodgkin's l...
In very-elderly diffuse large B-cell lymphoma (DLBCL) patients, treatment intensities must be lowere...
The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II ...
The use of non-pegylated liposomal doxorubicin (Myocet®) in diffuse large B-cell lymphoma (DLBCL) ha...
open12noAn update at 7 years was conceived for our multicenter phase II study in which 55 elderly hi...
Rituximab has improved response rates and overall survival in B-cell lymphoma (DLBCL). Radiotherapy ...
Diffuse large B-cell lymphoma (DLBCL) is the most frequently-occurring type of malignant lymphoma in...
Rajni Sinha1, Loretta J Nastoupil2, Christopher R Flowers11Department of Hematology/Medical Oncology...
The use of non-pegylated liposomal doxorubicin (Myocet®) in diffuse large B-cell lymphoma (DLBCL) ha...
Background: The introduction of rituximab (R) to conventional CHOP chemotherapy for newly diagnosed ...
This study was made possible by funding from TEVA Pharmaceuticals.JMS has received honoraria from Ro...